Trials / Recruiting
RecruitingNCT06613698
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 393 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK4532990 | GSK4532990 will be administered |
| DRUG | Placebo | Placebo will be administered |
Timeline
- Start date
- 2024-09-27
- Primary completion
- 2027-08-02
- Completion
- 2028-03-07
- First posted
- 2024-09-26
- Last updated
- 2026-04-01
Locations
131 sites across 18 countries: United States, Argentina, Australia, Canada, Denmark, France, Germany, Greece, Italy, Japan, Mexico, Poland, South Africa, South Korea, Spain, Sweden, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06613698. Inclusion in this directory is not an endorsement.